IZAFE B Stock Overview
A life-science company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
iZafe Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.20 |
| 52 Week High | SEK 0.48 |
| 52 Week Low | SEK 0.18 |
| Beta | 0.41 |
| 11 Month Change | -1.96% |
| 3 Month Change | 0% |
| 1 Year Change | -50.00% |
| 33 Year Change | -83.05% |
| 5 Year Change | -92.31% |
| Change since IPO | -96.92% |
Recent News & Updates
Shareholder Returns
| IZAFE B | SE Healthcare Services | SE Market | |
|---|---|---|---|
| 7D | -5.7% | -4.4% | -3.6% |
| 1Y | -50.0% | 48.3% | 12.3% |
Return vs Industry: IZAFE B underperformed the Swedish Healthcare Services industry which returned 48.3% over the past year.
Return vs Market: IZAFE B underperformed the Swedish Market which returned 12.3% over the past year.
Price Volatility
| IZAFE B volatility | |
|---|---|
| IZAFE B Average Weekly Movement | 10.6% |
| Healthcare Services Industry Average Movement | 5.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: IZAFE B's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: IZAFE B's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 7 | Anders Segerstrom | www.izafe.se |
iZafe Group AB (publ), a life-science company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home. The company provides Dosell, an automated drug dispenser that handles dose bags, facilitates and enables independent medication, and reminds and alerts if the current dose is not taken at the right time. It serves consumers, and public and private-sector care providers in Sweden, the Nordic region, and internationally.
iZafe Group AB (publ) Fundamentals Summary
| IZAFE B fundamental statistics | |
|---|---|
| Market cap | SEK 55.67m |
| Earnings (TTM) | -SEK 31.99m |
| Revenue (TTM) | SEK 6.29m |
8.8x
P/S Ratio-1.7x
P/E RatioIs IZAFE B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IZAFE B income statement (TTM) | |
|---|---|
| Revenue | SEK 6.29m |
| Cost of Revenue | SEK 6.38m |
| Gross Profit | -SEK 95.00k |
| Other Expenses | SEK 31.89m |
| Earnings | -SEK 31.99m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | -0.12 |
| Gross Margin | -1.51% |
| Net Profit Margin | -508.73% |
| Debt/Equity Ratio | 37.5% |
How did IZAFE B perform over the long term?
See historical performance and comparison